Investor Relations

To Our Stakeholders

Net Sales and Profits Grew, Centered on Double-Digit Growth in Overseas Geographic Regions

All Overseas Geographic Regions Deliver Double-Digit Growth, Particularly China and EMEA*1
Sharply Higher Profits, Benefiting from Effects of Higher Sales and Yen Depreciation (Against the U.S. Dollar and the Chinese Yuan)

During the first six months of the fiscal year ending March 31, 2016, the Group achieved increases in net sales, centered on higher sales overseas. Furthermore, profits benefited significantly from the effects of higher sales and the impact of yen depreciation against the U.S. dollar and the Chinese yuan. Net sales rose 22.9% year on year, with operating income up 32.6%, ordinary income up 25.9% and profit attributable to owners of the parent up 32.0%. At the exchange rates prevailing one year earlier, net sales would have been up 15.2% and operating income up 7.9%.

Robust sales of reagents led to increased sales in the Japanese market. All overseas geographic regions recorded double-digit sales increases, with sales being particularly favorable in the hematology*2 and hemostasis fields. Notably, sales in China surged 48.3% year on year, due to increases in the hemostasis, hematology and immunochemistry fields. These factors drove the Sysmex Group’s overseas sales ratio to 84.2%.

As performance in the first six months of the fiscal year outpaced our expectations at the beginning of the fiscal year, we have revised our earnings forecast for the full fiscal year ending March 31, 2016, with net sales and all profit categories now higher than initially forecast.

With regard to dividends, we now plan to increase dividends for the year to ¥44 per share, including a ¥4 (interim) dividend to commemorate the 20th anniversary of our listing, in addition to the amounts forecast at the beginning of the fiscal year (of interim and year-end dividends of ¥20 each). This amounts to the 14th consecutive year of dividend increases, and we intend to maintain stable dividend levels going forward.

*1 EMEA: Europe, the Middle East and Africa
*2 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

Hisashi Ietsugu
Chairman and CEO


Related Links
 - Presentation
 - Financial Data
 - Financial Statement


President and CEO Hisashi Ietsugu
Nov. 2015 
Hisashi Ietsugu
Chairman and CEO
Hisashi Ietsugu

Top of Investor Relation

Sysmex Corporation

Copyright© SYSMEX CORPORATION, All Rights Reserved.